The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety.
Identifieur interne : 000057 ( Main/Exploration ); précédent : 000056; suivant : 000058The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety.
Auteurs : Joseph V. Pergolizzi [États-Unis] ; Paul J. Christo [États-Unis] ; Jo Ann Lequang [États-Unis] ; Peter Magnusson [Suède]Source :
- Drug design, development and therapy [ 1177-8881 ] ; 2020.
Abstract
Peripherally acting μ-opioid receptor antagonists (PAMORAs) constitute a class of drugs which reverse opioid-induced constipation (OIC) with similar opioid analgesic effects. OIC differs from other forms of constipation in that it is an iatrogenic condition that occurs when an opioid acts on the dense network of μ-opioid receptors in the enteric system, which affect a variety of functions including gastrointestinal motility, secretion, and other factors that can cause bowel dysfunction. Unfortunately, laxative products, bowel regimens, dietary changes, and lifestyle modifications have limited effectiveness in preventing OIC, Opioid-associated adverse effect which occurs in 40% to 80% of opioid patients and may led to cessation of the treatment. PAMORAs are μ-receptor opioid antagonists specifically developed so that they have very limited ability to cross the blood-brain barrier and thus they are able to antagonize peripheral but not central μ-opioid receptors. PAMORAs are designed to have no effect on the analgesic benefits of opioid pain relievers but to relieve but antagonizing the effects of the opioid in the gastrointestinal system. The three main PAMORAS are methyltrexone (oral or parenteral), naldemedine (oral only), and naloxegol (oral only). Clinical studies demonstrate the safety and efficacy of these agents for alleviating constipation without diminishing the analgesic effect of opioid therapy. The aim of this narrative review to update the current status of PAMORAs for treating OIC in terms of safety and efficacy.
DOI: 10.2147/DDDT.S221278
PubMed: 32210534
PubMed Central: PMC7075239
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety.</title><author><name sortKey="Pergolizzi, Joseph V" sort="Pergolizzi, Joseph V" uniqKey="Pergolizzi J" first="Joseph V" last="Pergolizzi">Joseph V. Pergolizzi</name><affiliation wicri:level="2"><nlm:affiliation>NEMA Research, Inc., Naples, FL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>NEMA Research, Inc., Naples, FL</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Christo, Paul J" sort="Christo, Paul J" uniqKey="Christo P" first="Paul J" last="Christo">Paul J. Christo</name><affiliation wicri:level="1"><nlm:affiliation>Division of Pain Medicine, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Medicine, Baltimore, ML, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pain Medicine, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Medicine, Baltimore, ML</wicri:regionArea><wicri:noRegion>ML</wicri:noRegion></affiliation></author><author><name sortKey="Lequang, Jo Ann" sort="Lequang, Jo Ann" uniqKey="Lequang J" first="Jo Ann" last="Lequang">Jo Ann Lequang</name><affiliation wicri:level="2"><nlm:affiliation>NEMA Research, Inc., Naples, FL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>NEMA Research, Inc., Naples, FL</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Magnusson, Peter" sort="Magnusson, Peter" uniqKey="Magnusson P" first="Peter" last="Magnusson">Peter Magnusson</name><affiliation wicri:level="3"><nlm:affiliation>Cardiology Research Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Cardiology Research Unit, Department of Medicine, Karolinska Institute, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Centre for Research and Development, Uppsala University/Region, Gävleborg, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Centre for Research and Development, Uppsala University/Region, Gävleborg</wicri:regionArea><wicri:noRegion>Gävleborg</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32210534</idno><idno type="pmid">32210534</idno><idno type="doi">10.2147/DDDT.S221278</idno><idno type="pmc">PMC7075239</idno><idno type="wicri:Area/Main/Corpus">000223</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000223</idno><idno type="wicri:Area/Main/Curation">000223</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000223</idno><idno type="wicri:Area/Main/Exploration">000223</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety.</title><author><name sortKey="Pergolizzi, Joseph V" sort="Pergolizzi, Joseph V" uniqKey="Pergolizzi J" first="Joseph V" last="Pergolizzi">Joseph V. Pergolizzi</name><affiliation wicri:level="2"><nlm:affiliation>NEMA Research, Inc., Naples, FL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>NEMA Research, Inc., Naples, FL</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Christo, Paul J" sort="Christo, Paul J" uniqKey="Christo P" first="Paul J" last="Christo">Paul J. Christo</name><affiliation wicri:level="1"><nlm:affiliation>Division of Pain Medicine, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Medicine, Baltimore, ML, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pain Medicine, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Medicine, Baltimore, ML</wicri:regionArea><wicri:noRegion>ML</wicri:noRegion></affiliation></author><author><name sortKey="Lequang, Jo Ann" sort="Lequang, Jo Ann" uniqKey="Lequang J" first="Jo Ann" last="Lequang">Jo Ann Lequang</name><affiliation wicri:level="2"><nlm:affiliation>NEMA Research, Inc., Naples, FL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>NEMA Research, Inc., Naples, FL</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Magnusson, Peter" sort="Magnusson, Peter" uniqKey="Magnusson P" first="Peter" last="Magnusson">Peter Magnusson</name><affiliation wicri:level="3"><nlm:affiliation>Cardiology Research Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Cardiology Research Unit, Department of Medicine, Karolinska Institute, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Centre for Research and Development, Uppsala University/Region, Gävleborg, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Centre for Research and Development, Uppsala University/Region, Gävleborg</wicri:regionArea><wicri:noRegion>Gävleborg</wicri:noRegion></affiliation></author></analytic><series><title level="j">Drug design, development and therapy</title><idno type="eISSN">1177-8881</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Peripherally acting μ-opioid receptor antagonists (PAMORAs) constitute a class of drugs which reverse opioid-induced constipation (OIC) with similar opioid analgesic effects. OIC differs from other forms of constipation in that it is an iatrogenic condition that occurs when an opioid acts on the dense network of μ-opioid receptors in the enteric system, which affect a variety of functions including gastrointestinal motility, secretion, and other factors that can cause bowel dysfunction. Unfortunately, laxative products, bowel regimens, dietary changes, and lifestyle modifications have limited effectiveness in preventing OIC, Opioid-associated adverse effect which occurs in 40% to 80% of opioid patients and may led to cessation of the treatment. PAMORAs are μ-receptor opioid antagonists specifically developed so that they have very limited ability to cross the blood-brain barrier and thus they are able to antagonize peripheral but not central μ-opioid receptors. PAMORAs are designed to have no effect on the analgesic benefits of opioid pain relievers but to relieve but antagonizing the effects of the opioid in the gastrointestinal system. The three main PAMORAS are methyltrexone (oral or parenteral), naldemedine (oral only), and naloxegol (oral only). Clinical studies demonstrate the safety and efficacy of these agents for alleviating constipation without diminishing the analgesic effect of opioid therapy. The aim of this narrative review to update the current status of PAMORAs for treating OIC in terms of safety and efficacy.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">32210534</PMID><DateRevised><Year>2020</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1177-8881</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Drug design, development and therapy</Title><ISOAbbreviation>Drug Des Devel Ther</ISOAbbreviation></Journal><ArticleTitle>The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety.</ArticleTitle><Pagination><MedlinePgn>1009-1025</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/DDDT.S221278</ELocationID><Abstract><AbstractText>Peripherally acting μ-opioid receptor antagonists (PAMORAs) constitute a class of drugs which reverse opioid-induced constipation (OIC) with similar opioid analgesic effects. OIC differs from other forms of constipation in that it is an iatrogenic condition that occurs when an opioid acts on the dense network of μ-opioid receptors in the enteric system, which affect a variety of functions including gastrointestinal motility, secretion, and other factors that can cause bowel dysfunction. Unfortunately, laxative products, bowel regimens, dietary changes, and lifestyle modifications have limited effectiveness in preventing OIC, Opioid-associated adverse effect which occurs in 40% to 80% of opioid patients and may led to cessation of the treatment. PAMORAs are μ-receptor opioid antagonists specifically developed so that they have very limited ability to cross the blood-brain barrier and thus they are able to antagonize peripheral but not central μ-opioid receptors. PAMORAs are designed to have no effect on the analgesic benefits of opioid pain relievers but to relieve but antagonizing the effects of the opioid in the gastrointestinal system. The three main PAMORAS are methyltrexone (oral or parenteral), naldemedine (oral only), and naloxegol (oral only). Clinical studies demonstrate the safety and efficacy of these agents for alleviating constipation without diminishing the analgesic effect of opioid therapy. The aim of this narrative review to update the current status of PAMORAs for treating OIC in terms of safety and efficacy.</AbstractText><CopyrightInformation>© 2020 Pergolizzi Jr et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pergolizzi</LastName><ForeName>Joseph V</ForeName><Initials>JV</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>NEMA Research, Inc., Naples, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christo</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Division of Pain Medicine, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Medicine, Baltimore, ML, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LeQuang</LastName><ForeName>Jo Ann</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>NEMA Research, Inc., Naples, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magnusson</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiology Research Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Research and Development, Uppsala University/Region, Gävleborg, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Des Devel Ther</MedlineTA><NlmUniqueID>101475745</NlmUniqueID><ISSNLinking>1177-8881</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">constipation</Keyword><Keyword MajorTopicYN="N">methylnaltrexone</Keyword><Keyword MajorTopicYN="N">naldemedine</Keyword><Keyword MajorTopicYN="N">naloxegol</Keyword><Keyword MajorTopicYN="N">opioid antagonism</Keyword><Keyword MajorTopicYN="N">opioid-associated bowel disorder</Keyword><Keyword MajorTopicYN="N">opioid-associated side effects</Keyword><Keyword MajorTopicYN="N">pain</Keyword></KeywordList><CoiStatement>JVP Jr is a consultant/speaker or researcher for AstraZeneca, US World Meds, BDSI, Salix, Enalare, Scilex, and Neumentum and is a principal at Native Cardio. He also reports personal fees from BDSI, during the conduct of the study; grants and/or personal fees from Salix and Astra Zeneca, outside the submitted work. PJC is on the advisory board of GlaxoSmithKline, Consumer Healthcare and is a consultant for Daichii Sankyo. He also reports personal fees from GlaxoSmithKline, Daiichi Sankyo, and BTG, assisted in media work for Algiatry, outside the submitted work. PM has received speaker fees or grants from Abbott, Alylam, Bayer, AstraZeneca, BMS, Boeringer-Ingelheim, Internetmedicine AB, Lilly, Novo Nordsik, Octupus Medical, Orion Pharma, Pfizer and Vifor Pharma. The authors report no other conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>01</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32210534</ArticleId><ArticleId IdType="doi">10.2147/DDDT.S221278</ArticleId><ArticleId IdType="pii">221278</ArticleId><ArticleId IdType="pmc">PMC7075239</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clin Cancer Res. 2018 May 15;24(10):2319-2327</Citation><ArticleIdList><ArticleId IdType="pubmed">29511031</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Gastroenterol Hepatol. 2017 Aug;2(8):555-564</Citation><ArticleIdList><ArticleId IdType="pubmed">28576452</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2017 Mar;61:244-258</Citation><ArticleIdList><ArticleId IdType="pubmed">27939249</ArticleId></ArticleIdList></Reference><Reference><Citation>J Support Oncol. 2009 Jan-Feb;7(1):39-46</Citation><ArticleIdList><ArticleId IdType="pubmed">19278178</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2015 Jan;232(1):63-73</Citation><ArticleIdList><ArticleId IdType="pubmed">24871705</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2015 Jun 16;5:11389</Citation><ArticleIdList><ArticleId IdType="pubmed">26078009</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2014 Jun 19;370(25):2387-96</Citation><ArticleIdList><ArticleId IdType="pubmed">24896818</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 2015 Jan;172(2):251-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24467261</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gastrointestin Liver Dis. 2019 Mar;28(1):41-46</Citation><ArticleIdList><ArticleId IdType="pubmed">30851171</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurogastroenterol Motil. 2010 Apr;22(4):424-30, e96</Citation><ArticleIdList><ArticleId IdType="pubmed">20100280</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2011 May;106(5):835-42; quiz 843</Citation><ArticleIdList><ArticleId IdType="pubmed">21343919</ArticleId></ArticleIdList></Reference><Reference><Citation>J Opioid Manag. 2016 Nov/Dec;12(6):405-419</Citation><ArticleIdList><ArticleId IdType="pubmed">28059433</ArticleId></ArticleIdList></Reference><Reference><Citation>Reg Anesth Pain Med. 2016 Jan-Feb;41(1):93-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26650429</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 1995 Mar 24;276(1-2):107-11</Citation><ArticleIdList><ArticleId IdType="pubmed">7781680</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pain. 2011 Feb;12(2):175-84</Citation><ArticleIdList><ArticleId IdType="pubmed">21292168</ArticleId></ArticleIdList></Reference><Reference><Citation>J Surg Oncol. 2009 Dec 15;100(8):725-31</Citation><ArticleIdList><ArticleId IdType="pubmed">19722233</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Clin Oncol. 2017 Apr;22(2):397-404</Citation><ArticleIdList><ArticleId IdType="pubmed">27628064</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Mar 24;9(3):e91577</Citation><ArticleIdList><ArticleId IdType="pubmed">24662916</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Drug Dev. 2015 Nov;4(6):434-41</Citation><ArticleIdList><ArticleId IdType="pubmed">27137715</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliment Pharmacol Ther. 2014 Oct;40(7):771-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25112584</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hosp Med. 2012 Feb;7(2):67-72</Citation><ArticleIdList><ArticleId IdType="pubmed">21998076</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Investig Drugs. 2011 Aug;20(8):1047-56</Citation><ArticleIdList><ArticleId IdType="pubmed">21663526</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2008 May 29;358(22):2332-43</Citation><ArticleIdList><ArticleId IdType="pubmed">18509120</ArticleId></ArticleIdList></Reference><Reference><Citation>Pain Med. 2011 Dec;12(12):1727-37</Citation><ArticleIdList><ArticleId IdType="pubmed">22123184</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2016 Aug 12;6:31572</Citation><ArticleIdList><ArticleId IdType="pubmed">27514308</ArticleId></ArticleIdList></Reference><Reference><Citation>J Palliat Med. 2015 Jul;18(7):593-600</Citation><ArticleIdList><ArticleId IdType="pubmed">25973526</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Blood Cancer. 2013 Oct;60(10):1667-70</Citation><ArticleIdList><ArticleId IdType="pubmed">23766091</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2010 Jan;24(1):83-95</Citation><ArticleIdList><ArticleId IdType="pubmed">19679181</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pain Palliat Care Pharmacother. 2011;25(2):136-45</Citation><ArticleIdList><ArticleId IdType="pubmed">21657861</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin J Pain. 2019 Feb;35(2):174-188</Citation><ArticleIdList><ArticleId IdType="pubmed">30289777</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Biochem Biophys. 2013 May;66(1):53-63</Citation><ArticleIdList><ArticleId IdType="pubmed">22918821</ArticleId></ArticleIdList></Reference><Reference><Citation>Pain. 2004 Dec;112(3):372-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15561393</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2017 Dec 1;35(34):3859-3866</Citation><ArticleIdList><ArticleId IdType="pubmed">28968171</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pain Res. 2018 Dec 24;12:127-138</Citation><ArticleIdList><ArticleId IdType="pubmed">30613161</ArticleId></ArticleIdList></Reference><Reference><Citation>Pain Pract. 2018 Apr;18(4):505-514</Citation><ArticleIdList><ArticleId IdType="pubmed">28898536</ArticleId></ArticleIdList></Reference><Reference><Citation>Postgrad Med. 2016;128(3):282-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26839023</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr Oncol Nurs. 2006 Mar-Apr;23(2):65-74</Citation><ArticleIdList><ArticleId IdType="pubmed">16476780</ArticleId></ArticleIdList></Reference><Reference><Citation>Breast Cancer Res Treat. 2012 Jun;133(3):853-63</Citation><ArticleIdList><ArticleId IdType="pubmed">22042369</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pain. 2011 Feb;12(2):185-93</Citation><ArticleIdList><ArticleId IdType="pubmed">21292169</ArticleId></ArticleIdList></Reference><Reference><Citation>Pain Med. 2011 Aug;12(8):1223-30</Citation><ArticleIdList><ArticleId IdType="pubmed">21810165</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacokinet. 2017 Jun;56(6):573-582</Citation><ArticleIdList><ArticleId IdType="pubmed">28035588</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pain Symptom Manage. 2009 Nov;38(5):683-90</Citation><ArticleIdList><ArticleId IdType="pubmed">19713070</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Clin Evid. 2015 Sep 11;2015:</Citation><ArticleIdList><ArticleId IdType="pubmed">26360669</ArticleId></ArticleIdList></Reference><Reference><Citation>Pain Med. 2017 Dec 1;18(12):2350-2360</Citation><ArticleIdList><ArticleId IdType="pubmed">28371937</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs. 2015 Mar;75(4):419-25</Citation><ArticleIdList><ArticleId IdType="pubmed">25666542</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Drug Dev. 2017 Jul;6(4):420-427</Citation><ArticleIdList><ArticleId IdType="pubmed">28127938</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurogastroenterol Motil. 2004 Oct;16 Suppl 2:17-28</Citation><ArticleIdList><ArticleId IdType="pubmed">15357848</ArticleId></ArticleIdList></Reference><Reference><Citation>P T. 2018 Oct;43(10):601-627</Citation><ArticleIdList><ArticleId IdType="pubmed">30271103</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Drug Dev. 2018 Jun;7(5):474-483</Citation><ArticleIdList><ArticleId IdType="pubmed">28960888</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 2015 Aug 15;121(16):2681-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26043235</ArticleId></ArticleIdList></Reference><Reference><Citation>Pain. 2013 Sep;154(9):1542-50</Citation><ArticleIdList><ArticleId IdType="pubmed">23726675</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharm Sci. 2018 May 30;117:187-192</Citation><ArticleIdList><ArticleId IdType="pubmed">29432808</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr Gastroenterol Nutr. 2006 Sep;43(3):e1-13</Citation><ArticleIdList><ArticleId IdType="pubmed">16954945</ArticleId></ArticleIdList></Reference><Reference><Citation>Pain Med. 2017 Aug 1;18(8):1496-1504</Citation><ArticleIdList><ArticleId IdType="pubmed">28810695</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cardiovasc Pharmacol Ther. 2018 Jul;23(4):309-317</Citation><ArticleIdList><ArticleId IdType="pubmed">29504415</ArticleId></ArticleIdList></Reference><Reference><Citation>J Manag Care Spec Pharm. 2016 Mar;22(3):236-45</Citation><ArticleIdList><ArticleId IdType="pubmed">27003553</ArticleId></ArticleIdList></Reference><Reference><Citation>Pain Pract. 2015 Jul;15(6):564-71</Citation><ArticleIdList><ArticleId IdType="pubmed">24815199</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pain Symptom Manage. 2008 May;35(5):458-68</Citation><ArticleIdList><ArticleId IdType="pubmed">18440447</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesth Analg. 2011 Mar;112(3):558-67</Citation><ArticleIdList><ArticleId IdType="pubmed">21156980</ArticleId></ArticleIdList></Reference><Reference><Citation>Pain. 2018 May;159(5):987-994</Citation><ArticleIdList><ArticleId IdType="pubmed">29419653</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Surg. 2001 Nov;182(5A Suppl):11S-18S</Citation><ArticleIdList><ArticleId IdType="pubmed">11755892</ArticleId></ArticleIdList></Reference><Reference><Citation>Pain Pract. 2017 Jul;17(6):820-828</Citation><ArticleIdList><ArticleId IdType="pubmed">27860208</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2017 Jun 10;35(17):1921-1928</Citation><ArticleIdList><ArticleId IdType="pubmed">28445097</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2016 Nov;27(11):2032-2038</Citation><ArticleIdList><ArticleId IdType="pubmed">27573565</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Ther. 2013 Dec;35(12):1876-83</Citation><ArticleIdList><ArticleId IdType="pubmed">24238792</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Clin Pract. 2007 Jul;61(7):1181-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17488292</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pain Symptom Manage. 2011 Nov;42(5):754-60</Citation><ArticleIdList><ArticleId IdType="pubmed">22045373</ArticleId></ArticleIdList></Reference><Reference><Citation>Pain Med. 2009 Jan;10(1):35-42</Citation><ArticleIdList><ArticleId IdType="pubmed">18721170</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Drug Dev. 2015 Nov;4(6):442-8</Citation><ArticleIdList><ArticleId IdType="pubmed">27137716</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Pract. 2019 Oct;32(5):558-567</Citation><ArticleIdList><ArticleId IdType="pubmed">29207909</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Pharmacol. 2016 Apr;56(4):497-505</Citation><ArticleIdList><ArticleId IdType="pubmed">26248047</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Suède</li><li>États-Unis</li></country><region><li>Floride</li><li>Svealand</li></region><settlement><li>Stockholm</li></settlement></list><tree><country name="États-Unis"><region name="Floride"><name sortKey="Pergolizzi, Joseph V" sort="Pergolizzi, Joseph V" uniqKey="Pergolizzi J" first="Joseph V" last="Pergolizzi">Joseph V. Pergolizzi</name></region><name sortKey="Christo, Paul J" sort="Christo, Paul J" uniqKey="Christo P" first="Paul J" last="Christo">Paul J. Christo</name><name sortKey="Lequang, Jo Ann" sort="Lequang, Jo Ann" uniqKey="Lequang J" first="Jo Ann" last="Lequang">Jo Ann Lequang</name></country><country name="Suède"><region name="Svealand"><name sortKey="Magnusson, Peter" sort="Magnusson, Peter" uniqKey="Magnusson P" first="Peter" last="Magnusson">Peter Magnusson</name></region><name sortKey="Magnusson, Peter" sort="Magnusson, Peter" uniqKey="Magnusson P" first="Peter" last="Magnusson">Peter Magnusson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/WillowV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000057 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000057 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= WillowV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32210534
|texte= The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32210534" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a WillowV1
| This area was generated with Dilib version V0.6.37. |  |